Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

A 2022 study found that people who stopped taking semaglutide and making lifestyle changes for 1 year regained two-thirds of the weight they had lost. For the best weight loss results, try ...

A clinical trial shows that people who were considered by medical researchers to report signs of alcohol use disorder drank significantly less after taking semaglutide for two months, compared to ...

The drug — the brand name for the GLP-1 agonist semaglutide — “significantly reduced weekly alcohol craving,” according to a study published Wednesday, Feb. 12, in the Journal of the ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

"Adherence improves when treatment integrates easily into patients’ lives," explains Adam McBride, Eden’s CEO. Eden’s digital ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

Semaglutide prescription initiation predictors included female sex and use of antidepressants among patients with obesity without diabetes.

Semaglutide is now approved for T2D patients ... glomerular filtration rate (eGFR), as well as an eGFR less than 15 mL/min/1.73 m 2. Outcomes related to CV or renal death, as well as chronic ...

At the recent SEC meeting for Endocrinology and Metabolism held on 13th January 2025, the expert panel reviewed the ...